EXPRESSION OF CYTOCHROME-P450 2D6 IN ESCHERICHIA-COLI, PURIFICATION, AND SPECTRAL AND CATALYTIC CHARACTERIZATION

被引:108
作者
GILLAM, EMJ
GUO, ZY
MARTIN, MV
JENKINS, CM
GUENGERICH, FP
机构
[1] UNIV QUEENSLAND,DEPT PHYSIOL & PHARMACOL,ST LUCIA,QLD 4072,AUSTRALIA
[2] VANDERBILT UNIV,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232
[3] VANDERBILT UNIV,SCH MED,CTR MOLEC TOXICOL,NASHVILLE,TN 37232
关键词
P450; 2D6; ESCHERICHIA COLI; HETEROLOGOUS EXPRESSION; ENZYME PURIFICATION; DEBRISOQUINE; BUFURALOL;
D O I
10.1006/abbi.1995.1329
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cytochrome P450 (P450) 2D6 is the classic human liver debrisoquine 4-hydroxylase, the first human P450 for which genetic polymorphism was clearly demonstrated, We prepared 11 different constructs of P450 2D6, with modification at the N-terminus, for expression in Escherichia coli with the vector pCW. These varied considerably in levels of expression of apo- and holoprotein, with the best yield being obtained in a system in which much of the N-terminal hydrophobic segment was removed. Production of holoprotein was highly dependent upon the addition of delta-aminolevulinic acid and FeCl3 to cultures, even though heme production should not be limiting in this system, The expressed protein was not tightly bound to the ''heavier'' membrane fraction but did not appear to behave as a soluble protein either, A purification strategy was developed involving fractional centrifugation, Triton X-114 phase separation, and flavodoxin affinity chromatography, which led to recovery of apparently electrophoretically homogeneous protein in good yield, Purified P450 2D6 had the expected N-terminal amino acid sequence and catalytic activities toward debrisoquine (4-hydroxylation) and bufuralol (1'-hydroxylation), The availability of a ready source of the recombinant protein should facilitate physical as well as functional studies and antibody production for other uses. (C) 1995 Academic Press, Inc.
引用
收藏
页码:540 / 550
页数:11
相关论文
共 87 条
[1]  
ARMSTRONG M, 1993, HUM GENET, V91, P616
[2]   THE CYTOCHROME-P450 CYP2D6 ALLELIC VARIANT CYP2D6J AND RELATED POLYMORPHISMS IN A EUROPEAN POPULATION [J].
ARMSTRONG, M ;
FAIRBROTHER, K ;
IDLE, JR ;
DALY, AK .
PHARMACOGENETICS, 1994, 4 (02) :73-81
[3]  
ARMSTRONG M, 1992, LANCET, P1017
[4]   METABOLIC OXIDATION PHENOTYPES AS MARKERS FOR SUSCEPTIBILITY TO LUNG-CANCER [J].
AYESH, R ;
IDLE, JR ;
RITCHIE, JC ;
CROTHERS, MJ ;
HETZEL, MR .
NATURE, 1984, 312 (5990) :169-170
[5]  
BARBEAU A, 1987, CAN J NEUROL SCI, V14, P36
[6]  
BARBEAU A, 1985, LANCET, P1213
[7]   EXPRESSION AND ENZYMATIC-ACTIVITY OF RECOMBINANT CYTOCHROME-P450 17-ALPHA-HYDROXYLASE IN ESCHERICHIA-COLI [J].
BARNES, HJ ;
ARLOTTO, MP ;
WATERMAN, MR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (13) :5597-5601
[8]  
BARNES HJ, 1992, THESIS U TEXAS SW ME
[9]   NORTRIPTYLINE AND ANTIPYRINE CLEARANCE IN RELATION TO DEBRISOQUINE HYDROXYLATION IN MAN [J].
BERTILSSON, L ;
EICHELBAUM, M ;
MELLSTROM, B ;
SAWE, J ;
SCHULZ, HU ;
SJOQVIST, F .
LIFE SCIENCES, 1980, 27 (18) :1673-1677
[10]   PURIFICATION OF A DESMETHYLIMIPRAMINE AND DEBRISOQUINE HYDROXYLATING CYTOCHROME-P-450 FROM HUMAN-LIVER [J].
BIRGERSSON, C ;
MORGAN, ET ;
JORNVALL, H ;
VONBAHR, C .
BIOCHEMICAL PHARMACOLOGY, 1986, 35 (18) :3165-3166